论文部分内容阅读
暴发型乙型肝炎是乙型肝炎病毒(HBV)急性感染的少见严重并发症,成人的病死率达82％,且任何药物及治疗措施均不能使病死率降低。曾设想用抑制病毒增殖的药物治疗本病,但只有在HBV仍正在增殖时才能认为应用这些药物是正确的。在暴发型乙型肝炎时曾报道乙型肝炎表面抗原(HBsAg)能从血中迅速被清除,并归因于增强的免疫反应,但这可能与HBV中止增殖有关,或与HBV继续增殖和合成HBsAg,而HBsAg又被大量产生的抗-HBs所掩盖有关。为了确定HBV的增殖是中止还是继续,作者研究了暴发型乙型肝炎患者的血清中是否有乙型肝炎e抗原(HBeAg)和HBV DNA,而在血清中
Outbreak of hepatitis B is a rare and serious complication of acute hepatitis B virus infection in adults, with a mortality rate of 82% in adults and no mortality or any reduction in any drug or treatment. It has been envisaged to treat this disease with drugs that inhibit the proliferation of the virus, but the application of these drugs is considered correct only if HBV is still proliferating. It has been reported during outbreaks of hepatitis B that hepatitis B surface antigen (HBsAg) is rapidly cleared from the blood and is due to an enhanced immune response, but this may be related to the abrogation of HBV proliferation or to its continued proliferation and synthesis with HBV HBsAg, which is overshadowed by the mass production of anti-HBs. In order to determine whether HBV proliferation is aborted or continued, the authors investigated whether the serum of patients with fulminant hepatitis B had hepatitis B e antigen (HBeAg) and HBV DNA, whereas in serum